
CLGN Stock Forecast & Price Target
CLGN Analyst Ratings
Bulls say
CollPlant Biotechnologies Ltd demonstrates a strong positive outlook due to its innovative rhCollagen-based products, particularly the Collink.3D bioink, which has shown superior performance in structured tissue formation compared to animal-derived alternatives, thereby enhancing its competitive edge in the bioprinting market. The operational U.S. logistics center is expected to drive incremental sales of both BioInk and rhCollagen as demand grows among research institutions and tissue-engineering clients. Additionally, the strategic partnership with Allergan and advancements in regulatory approvals for its dermal filler program position the company well for increased revenue and growth in both regenerative and aesthetic medicine sectors.
Bears say
CollPlant Biotechnologies Ltd faces a challenging financial environment, as evidenced by its recent $2.0 million capital raise, which has resulted in a negative market reaction and raised concerns about investor confidence. The company's pricing actions, particularly at $1.25 per share, indicate persistent pressure on equity and suggest limited opportunities for effective capital formation. Furthermore, revised forecasts for key product segments like Dermal Fillers and BioInk, along with the removal of Breast Implants from projections, highlight a more conservative outlook that may adversely impact future revenue growth.
This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.
CLGN Analyst Forecast & Price Prediction
Start investing in CLGN
Order type
Buy in
Order amount
Est. shares
0 shares